EGFR inhibitors: What have we learned from the treatment of lung cancer?

Nature Clinical Practice Oncology

Volumn 2, Issue 11, 2005, Pages 554-561

  Giaccone, Giuseppe ^a   Rodriguez, Jose Antonio ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Amplification; EGFR inhibitors; EGFR mutations; Lung cancer; Resistance

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB; VANDETANIB;

ADENOCARCINOMA; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ASIAN; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; GASTROINTESTINAL STROMAL TUMOR; GENDER; GENE MUTATION; GENE SEQUENCE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; REVIEW; SINGLE STRAND CONFORMATION POLYMORPHISM; TREATMENT FAILURE; UNITED STATES; WILD TYPE;

ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 28444468144     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0341     Document Type: Review

References (57)

1. Parkin DM et al. (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108
2. Dubey S et al. (2005) Three emerging new drugs for NSCLC: Pemetrexed, bortezomib, and cetuximab. Oncologist 10: 282-291
3. Herbst RS et al. (2005) Angiogenesis and lung cancer: Prognostic and therapeutic implications. J Clin Oncol 23: 3243-3256
4. Giaccone G (2005) Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. J Clin Oncol 23: 3235-3242
5. Paez JG et al. (2004) EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304: 1497-1500
6. Lynch TJ et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139
7. Pao W et al. (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101: 13306-13311
8. Sordella R et al. (2004) Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305: 1163-1167
9. Tracy S et al. (2004) Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res 64: 7241-7244
10. Fabian MA et al. (2005) A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23: 329-336
11. Settleman J (2004) Inhibition of mutant EGF receptors by gefitinib: targeting an achilles' heel of lung cancer. Cell Cycle 3: 1496-1497
12. Janne PA et al. (2005) Epidermal growth factor receptor mutations in non-small-cell lung cancer: Implications for treatment and tumor biology. J Clin Oncol 23: 3227-3234
13. Shepherd FA et al. (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123-132
14. Janmaat ML et al. (2003) Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: Limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 9: 2316-2326
15. Janmaat M et al. Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or PI3K pathways in non-small cell lung cancer cells. Int J Cancer [doi: 10.1002/ijc.21290]
16. Fukuoka M et al. (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21: 2237-2246
17. Kris MG et al. (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 290: 2149-2158
18. Chou TY et al. (2005) Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res 11: 3750-3757
19. Mitsudomi T et al. (2005) Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 23: 2513-2520
20. Pao W and Miller VA (2005) Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 23: 2556-2568
21. Marchetti A et al. (2005) EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 23: 857-865
22. Donohoe E (2005) Denaturing high-performance liquid chromatography using the WAVE DNA fragment analysis system. Methods Mol Med 108: 173-187
23. Takano T et al. (2005) Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol [doi: 10.1200/ JCO.2005.01.0793]
24. Dressler LG et al. (2005) Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J Clin Oncol 23: 4287-4297
25. Cappuzzo F et al. (2003) Gefitinib in pretreated non-small-cell lung cancer (NSCLC): Analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J Clin Oncol 21: 2658-2663
26. Parra HS et al. (2004) Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer. Br J Cancer 91: 208-212
27. Perez-Soler R et al. (2004) Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 22: 3238-3247
28. Cappuzzo F et al. (2005) Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97: 643-655
29. Tsao MS et al. (2005) Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 353: 133-144
30. Hirsch FR et al. (2005) Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: A Southwest Oncology Group Study. J Clin Oncol [doi: 10.1200/JCO.2005.01.2823]
31. Amann J et al. (2005) Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res 65: 226-235
32. Stephens P et al. (2004) Lung cancer: Intragenic ERBB2 kinase mutations in tumours. Nature 431: 525-526
33. Shigematsu H et al. (2005) Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 65: 1642-1646
34. Kosaka T et al. (2004) Mutations of the epidermal growth factor receptor gene in lung cancer: Biological and clinical implications. Cancer Res 64: 8919-8923
35. Pao W et al. (2005) KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2: E17
36. Soung YH et al. (2005) Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas. Virchows Arch 446: 483-488
37. Shigematsu H et al. (2005) Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97: 339-346
38. Rodenhuis S et al. (1988) Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res 48: 5738-5741
39. Herbst RS et al. (2004) TRIBUTE - A phase III trial of erlotinib HCI (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol 22 (Suppl 14): S619
40. Eberhard DA et al. (2005) Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol [doi: 10.1200/ JCO.2005.02.857]
41. Cappuzzo F et al. (2004) Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 96: 1133-1141
42. Pao W et al. (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2: E73
43. Kobayashi S et al. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352: 786-792
44. Toyooka S et al. (2005) EGFR mutation and response of lung cancer to gefitinib. N Engl J Med 352: 2136
45. Shih J-Y et al. (2005) EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer. N Engl J Med 353: 207-208
46. Chen LL et al. (2004) A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res 64: 5913-5919
47. Azam M et al. (2003) Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112: 831-843
48. Carter TA et al. (2005) Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci U S A 102: 11011-11016
49. Han SW et al. (2005) Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 23: 2493-2501
50. Lilenbaum R et al. (2005) A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer [abstract]. J Clin Oncol 23: S629
51. Tsuchihashi Z et al: (2005) Responsiveness to cetuximab without mutations in EGFR. N Engl J Med 353: 208-209
52. Raez LE et al. (2005) Clinical responses to gefinitib after failure of treatment with cetuximab in advanced non-small-cell lung cancer. J Clin Oncol 23: 4244-4245
53. Huang SF et al. (2004) High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 10: 8195-8203
54. Kim KS et al. (2005) Predictors of the response to gefitinib in refractory non-small cell lung cancer. Clin Cancer Res 11: 2244-2251
55. Tokumo M et al. (2005) The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 11: 1167-1173
56. Mu XL et al. (2005) Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer. Clin Cancer Res 11: 4289-4294
57. Cortes-Funes H et al. (2005) Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. Ann Oncol 16: 1081-1086